PUBLICATION

January 11, 2021

[Moscow – 11.01.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, has published its recent scientific research on identifiability in PLOS Computational Biology.

Read more about InSysBio to publish the new article on identifiability analysis in PLOS Computational Biology

InSysBio to run Heta video tutorial on YouTube

November 27, 2020

InSysBio has recently launched weekly series on YouTube about the Heta language.

Heta is a modeling language for quantitative systems pharmacology and systems biology. Now InSysBio presents the tutorial consisting of short lessons that familiarize with Heta, describe its features and show examples.

Read more about InSysBio to run Heta video tutorial on YouTube

InSysBio to share new data in frames of its Open Source QSP model of COVID-19

August 3, 2020

InSysBio has received a new set of results in framework of development of QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.

Read more about InSysBio to share new data in frames of its Open Source QSP model of COVID-19

InSysBio to evolve its Open Source QSP model of COVID-19

July 24, 2020

InSysBio has presented a new portion of results in the framework of development of COVID-19 QSP model.

Read more about InSysBio to evolve its Open Source QSP model of COVID-19

InSysBio to present COVID-19 QSP model further development

June 30, 2020

InSysBio continues to move forward in COVID-19 QSP model development. Its aim is to describe virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.

Read more about InSysBio to present COVID-19 QSP model further development

InSysBio team posters to be presented at AACR Virtual Annual Meeting II

CONFERENCE

June 22, 2020

AACR Virtual Annual Meeting II has begun! American Association for Cancer Research Annual Meeting is held virtually this year on June 22-24 due to COVID-19 spread. Today InSysBio team's posters were published on AACR website

Read more about InSysBio team posters to be presented at AACR Virtual Annual Meeting II

InSysBio modelers evaluated tau protein phosphorylation related targets for Alzheimer’s disease treatment

February 26, 2018

InSysBio continues to investigate the mechanisms underlying Alzheimer’s disease (AD) using the quantitative systems pharmacology (QSP) modeling approach. The part of QSP model describing tau protein was published in the PLOS ONE journal. This is one of more than dozen InSysBio publications in AD area during last seven years.

Read more about InSysBio modelers evaluated tau protein phosphorylation related targets for Alzheimer’s disease treatment

Computer model showed an optimal anti-amyloid treatment

Moscow, Russia, September 28, 2017. One must activate amyloid degradation as soon as possible to prevent the appearance of the protein plaques in brain under Alzheimer’s conditions. This conclusion was reached by scientists from the biotechnology company InSysBio, who created the first computer model of the disease. The final part of the work has been recently published in CPT: Pharmacometrics & Systems Pharmacology.

Read more about Computer model showed an optimal anti-amyloid treatment

To predict unpredictable: a platform for modeling of the high-selective oncology drugs was created

Moscow, Russia, July 14, 2017. The scientists from BIND RUS and InSysBio (www.insysbio.ru) published a joint research of the new class of anti-oncology treatment in the Journal of Controlled Release. Unique nanoparticles enriched with medications can deliver its content targeted to the tumor site, and the parameters of their effectiveness are programmed during the forming phase.

Read more about To predict unpredictable: a platform for modeling of the high-selective oncology drugs was created

System pharmacology modelers throw light on drug discovery in Alzheimer's

Moscow, Russia - 21 June, 2017. InSysBio scientific group led by Tatiana Karelina developed a quantitative system pharmacology model of Alzheimer’s disease. First part published in CPT PSP shows how to design initial phases of clinical trials of new drugs and to interpret the data obtained.